Novartis to acquire Ziarco Group to boost dermatology portfolio
Insight Weekly: Loan delinquencies up; US money supply falls; coal employment grows
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Novartis AG agreed to acquire Ziarco Group Ltd., a privately held company focused on developments of novel treatments in dermatology, for an undisclosed sum.
The acquisition will add a once-daily oral H4 receptor antagonist in development for eczema to Novartis' dermatology portfolio and pipeline.
The transaction is subject to customary closing conditions, including regulatory approval.
